Lehdistötiedote17.3.2025 klo 11.05BioStock: Last trading day for Abliva - the company leaves Nasdaq Stockholm
Pörssitiedote25.2.2025 klo 8.50Abliva applies for delisting and will convene an extraordinary general meeting
Pörssitiedote15.12.2024 klo 19.00Statement by the Board of Directors of Abliva regarding the public cash offer from Pharming
Lehdistötiedote9.12.2024 klo 7.32Abliva Announces Publication of Results from Phase 1a/b Study of KL1333 in the Scientific Journal Brain
Lehdistötiedote4.11.2024 klo 10.00Abliva will present at the BioStock Life Science Summit, November 21
Lehdistötiedote16.9.2024 klo 6.30Join Abliva for World Mitochondrial Disease Week 2024, September 16 – 22
Lehdistötiedote26.8.2024 klo 6.46BioStock: Abliva's CEO - We are the leading programme in mitochondrial disease
Pörssitiedote19.7.2024 klo 6.30Positive interim analysis in Abliva's FALCON study triggers convertible loan conversion
Pörssitiedote18.7.2024 klo 20.22Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease